trending Market Intelligence /marketintelligence/en/news-insights/trending/v2it97gO5VZ5qtwJRl9L5Q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Bausch Health, Glenmark settle patent dispute over plaque psoriasis lotion

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bausch Health, Glenmark settle patent dispute over plaque psoriasis lotion

Bausch Health Cos. Inc. and Mumbai, India-based pharmaceutical company Glenmark Pharmaceuticals Ltd. agreed to settle the intellectual property lawsuit regarding Bausch's plaque psoriasis treatment Bryhali.

Under the agreement, Glenmark will have nonexclusive rights to market a royalty-free generic version of the lotion effective 2026 or earlier under certain circumstances, subject to approval from the U.S. Food and Drug Administration.

Canada-based Bausch received tentative approval for Bryhali from the FDA in October 2018 to treat plaque psoriasis in adults.

Plaque psoriasis is the most common form of psoriasis, in which the skin is red and covered with silvery scales or patches.

As part of the settlement, Glenmark acknowledged Bausch's patents for the lotion. Final patent expiry on Bryhali Lotion is 2031.